Q4 2022 Results

Company overview Financial review 2023 priorities Appendix FINANCIAL PROFILE Novartis excluding and including Sandoz 2023 full year guidance Expected, barring unforeseen events; growth vs. PY in cc Innovative Medicines (IM) Novartis ex. Sandoz (IM + Corporate) Novartis incl. Sandoz (IM + Sandoz + Corporate)1 Key assumptions: Sales expected to grow low-to-mid single digit Core Oplnc expected to grow mid-to-high single digit Sales expected to grow low-to-mid single digit Core Oplnc expected to grow mid-to-high single digit Sales expected to grow low-to-mid single digit Core Oplnc expected to grow mid single digit ■ Our guidance assumes that we see a continuing return to normal global healthcare systems, including prescription dynamics, and that no SandostatinⓇ LAR generics enter in the US in 2023 ■ We continue to expect that the planned Sandoz spin-off is completed in H2 2023 1. Novartis Group guidance, assuming Sandoz would remain within the Group for the entire FY 2023 41 Investor Relations | Q4 2022 Results U NOVARTIS | Reimagining Medicine

View entire presentation